BREVITY

BREVITY: 

A phase II study of brentuximab vedotin using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity

Change of Staff

If there is a change of staff working on the trial please print off and complete the relevant registration form below. Please also ensure that the Signature and Delegation Log is updated. Return both documents to the BREVITY Trial Office.

Trial Documents

Links to the current protocol, Patient Information Sheet, Informed Consent Form are provided below. If there has been a recent amendment to the trial please ensure you have R&D approval before using these documents.

Other documents (e.g. Amendments, Case Report Form, Serious Adverse Event Form, Guidelines, GP Letter, Release of Medical Information Form etc) can be found by clicking on the other menu items below. If you cannot find what you are looking for please contact the BREVITY Trial Office.

Protocol

Patient Sheets

Version Control Lists

The version numbers and dates of all documents used for the trial are captured on a Version Control List. Links to the Version Control Lists used in this trial are below in reverse date order.

Investigator Site Folder

Pharmacy Folder

Amendments

Below is a link to a document which lists all of the substantial protocol amendments which have been made for this trial. The folders below contain the relevant amended documentation and approval letters. Please ensure that you have R&D approval (if applicable) before using the latest versions of these documents.

 

 Guidelines

Other Trial Documents

Case Report Forms

Case Report Forms

All CRFs [.zip]

Publications

To date there are no publications for this trial.

An abstract has been submitted to ISHL 10 for October 2016

News and Events

The BREVITY trial is now fully recruited.  Site closure will occur once all patients have completed treatment and follow-up. 

Newsletters

June 2016 [.pdf]

Christmas 2015 [.pdf]

March 2015 [.pdf]

Christmas 2014 [.pdf]

September 2013 [.pdf]

Contact Details

Chief Investigator
Prof John Radford
Department of Medical Oncology, Christie Hospitals NHS Foundation Trust, Wilmslow Raod, Mancheter, M20 4BX

Email:  BREVITY@trials.bham.ac.uk 

Tel:      +44 (0)161 446 3753

BREVITY Trial Office
Trial Coordinator:                               Dr Eszter Nagy                                   
Trial Management Team Leader:    Miss Shamyla Siddique
Trial Statistician:                                 Miss Sarah Pirrie

Cancer Research UK Clinical Trials Unit (CRCTU)
Institute of Cancer and Genomic Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT

Enquiries
Telephone: +44 (0)121 414 7673
Fax:             +44 (0)121 414 6061
Email:        BREVITY@trials.bham.ac.uk

Trial Entry
Telephone: +44  (0)800 371 969                         (9.00 am till 5.00 pm Monday to Friday)

Serious Adverse Event Reporting
Fax: +44 (0) 121 414 6061            or +44 (0) 121 414 3700

Sponsor

University of Birmingham